AR SB361

Exempts dialysate (composed of dextrose or icodextrin) and devices for home peritoneal kidney dialysis from specified pharmacy practice laws when used by patients with end stage renal disease.

Requires dialysate and devices to be FDA-approved or cleared, lawfully held by a manufacturer or registered third-party logistics provider, and delivered in original sealed packaging from the manufacturing facility.

Permits delivery only by the manufacturer or third-party logistics provider upon receipt of a physician's order by a licensed pharmacy and transmittal of an order from the pharmacy to the manufacturer.

Restricts delivery to either patients or designees for self-administration, or to healthcare providers and institutions for patient administration.

Requires the Arkansas State Board of Pharmacy to maintain oversight of all other drugs used in home peritoneal kidney dialysis and mandates retention of all dialysate sales and distribution records according to state law.